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Abstract Innate immunity may activate paracrine cir-
cuits able to entail vascular system in the onset and pro-
gression of several chronic degenerative diseases. In
particular, interleukin (IL)-12 triggers a genetic program in
lymphomononuclear cells characterized by the production
of interferon-c and specific chemokines resulting in an
angiostatic activity. The aim of this study is to identify
molecules involved in the regulation of cell cycle in
endothelial cells co-cultured with IL-12-stimulated lym-
phomonuclear cells. By using a transwell mediated co-
culture system we demonstrated that IL-12-stimulated
lymphomonuclear cells induce an arrest of endothelial cells
cycle in G1, which is mainly mediated by the up-regulation
of p21Cip1/Waf1, an inhibitor of cyclin kinases. This effect
requires the activation of STAT1, PKCd and p38 MAPK,
while p53 is ineffective. In accordance, siRNA-dependent
silencing of these molecules in endothelial cells inhibited
the increase of p21Cip1/Waf1 and the modification in cell
cycle promoted by IL-12-stimulated lymphomonuclear
cells. These results indicate that the angiostatic action of
IL-12-stimulated lymphomononuclear cells may lie in the
capability to arrest endothelial cells in G1 phase through a
mechanisms mainly based on the specific up-regulation of
p21Cip1/Waf1 induced by the combined activity of STAT1,
PKCd and p38 MAPK.
Keywords Angiogenesis  Cell proliferation  Cytokines 
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Introduction
Tumor aggressiveness is preceded by a prominent vascu-
larization, caused by an alteration of homeostasis between
endogenous inhibitors and inducers of angiogenesis [1].
This unbalance is mainly caused by mutations of molecules
involved in the control of transcription of angiogenesis
related genes [1] and by networks occurring between
cancer and inflammatory cells [2]. Activation of these
circuits results in the formation of a chaotic and inefficient
circulation, which represents the final target of anti-
angiogenic therapies aimed to normalize, rather than to
inhibit, the architecture and the function of tumor vascu-
lature [3]. A similar scenario occurs in chronic inflamma-
tory diseases [4], including atherosclerosis [5]. The clinical
significance of plaque neovascularization is indicated by
studies that show a higher prevalence of angiogenesis in
atherosclerotic lesions characterized by plaque instability
[6, 7]. Endogenous angiogenesis inhibitors are produced
during normal or pathological situations and may be
Marina Strasly and Claudia Meda contributed equally to this work.
Electronic supplementary material The online version of this
article (doi:10.1007/s10456-012-9286-9) contains supplementary
material, which is available to authorized users.
L. Napione (&)  M. Strasly  C. Meda  S. Mitola  M. Alvaro 
G. Doronzo  S. Marchio`  E. Giraudo  M. Arese  F. Bussolino
Department of Oncological Sciences, Institute for Cancer
Research and Treatment, University of Torino,
10060 Candiolo, Torino, Italy
e-mail: lucia.napione@ircc.it
Present Address:
S. Mitola
Department of Biological Sciences and Biotechnology,
University of Brescia, 25123 Brescia, Italy
L. Primo
Department of Clinical and Biological Sciences,
University of Torino, San Luigi Gonzaga Hospital,
10043 Orbassano, Torino, Italy
123
Angiogenesis (2012) 15:713–725
DOI 10.1007/s10456-012-9286-9
cryptic domains of matrix proteins cleaved by matrix
metalloproteinases, or soluble molecules taking part in
tissue homeostasis, including cytokines and chemokines
[1]. Within cytokines, interleukin (IL)-12 is a powerful
inhibitor of tumor progression [reviewed in [8]]. It is
mainly involved in connecting innate and adaptive immu-
nity through the production of interferon (IFN)c [9].
Numerous preclinical and clinical studies have demon-
strated that the inhibition of tumor growth is mediated by
multiple activities of IL-12 including Th1 responses, CD8?
cell-, NK cell- and granulocyte-mediated cytotoxicity, and
vascular targeting. Besides promoting tumor ischemic-
hemorrhagic necrosis by recruiting leucocytes, IL-12
inhibits angiogenesis [10–14], without a direct stimulation
of endothelial cells (ECs) [15]. This effect appears to be
dependent on the ability of T and NK cells stimulated by
IL-12 to release IFNc, which modulates the induction of
angiostatic chemokines CXCL9, CXCL10 and CXCL11
[14, 16, 17]. These chemokines exert their activity by
activating CXCR3B receptor expressed on ECs [18] and
inhibiting the motility and the proliferation triggered by
angiogenic inducers [16, 17, 19–21].
Furthermore the IL-12/IFNc/chemokine axis participates
in regulatory networks occurring between lymphocytes and
ECs. By using a co-culture model avoiding cell contact we
previously demonstrated that this axis delays the entry of
ECs into S phase of their duplicative cycle without
affecting survival, and alters proteolytic homeostasis,
resulting in the inhibition of in vitro formation of capillary-
like structures [22, 23].
Cell-cycle progression relies on the activation of cyclins
and cyclin-dependent kinases (CDK), which sequentially act
together in G1 to initiate S phase and in G2 to initiate mitosis.
These events are negatively regulated by two families of
inhibitors. Inhibitor of cyclin-dependent kinase (INK)4 pro-
teins, including p15, p16, p18 and p19, characterize the first
class, which is specific for CDK4–6 and therefore its regula-
tory role is restricted to the early G1 phase. The second family
is composed of Cip/Kip proteins, including p21, p27 and p57,
and is not specific for a particular phase of the cycle [24]. In
this study we report that IL-12-stimulated peripheral blood
mononuclear cells (PBMCs) inhibit angiogenesis in chick
chorion allantoid membrane (CAM) angiogenesis assay and
describe specific stimulation of CDK inhibitor p21Cip1/Waf1 in
ECs triggered by PBMCs stimulated with IL-12.
Materials and methods
Cells
Human ECs from cord umbilical veins and PBMCs were
prepared and used as described previously [22, 23, 25].
Purified NK cells from PBMCs were obtained by magnetic
bead isolation using MACS NK Negative Isolation kit
(Miltenyi Biotech), according to the manufacturer’s
instructions. Purity was assessed by Cyan ADP cytofluo-
rimeter (Beckman–Coulter). NK cells were routinely
purified to[93 % with an average of 0.5 % contaminating
CD14? accessory cells. To purify CD4? and CD8? [22],
PBMCs were depleted of adherent cells by two 1-h rounds
of adherence to plastic on tissue culture dishes at 37 C.
Non-adherent cells were then incubated overnight at 4 C
on a disk rotator with a combination of Abs against line-
age-specific markers (HLA class II, CD19, CD14, CD56,
CD11b, glycophorin, and CD4 or CD8; BD Biosciences).
Subsequently, cells were washed, counted and incubated
with magnetic beads coated with anti-mouse IgG mAbs
(Dynal; final dilution, 40 beads/cell). After incubation,
CD4? or CD8? T cells were separated by negative
immunomagnetic selection. The purity of the cellular
subset evaluated by cytofluorimeter analysis was [95 %.
Mouse spleen cells (SPCs) were isolated from C57BL/6
mice (Charles River) [23]. Mouse aortic ECs were isolated
from 12 weeks old p53-/- mice (C57BL/6J-Trp53tm1Tyj)
and p21Cip1/Waf1-/- mice (B6;129S2-Cdkn1atm1Tyj/J) (The
Jackson Laboratory). Briefly, aortas were longitudinally
opened, and placed with the intimal side downward onto a
collagen I matrix in M199 medium (Sigma–Aldrich) sup-
plemented with 10 % fetal calf serum (FCS) and 100 lg/mL
EC growth supplement (Calbiochem) for 6 days. After
tissue removal, trypsinized cells were pelleted and main-
tained on fibronectin-coated plates in endothelial basal
medium (Sigma–Aldrich) [26]. ECs were characterized by
cytofluorimeter analysis and were more than 92 % positive
for Flk-1 (R&D Systems) and mucosal vascular addressin
cell adhesion molecule-1 (Abcam).
Cell stimulation
PBMCs, CD4? cells, CD8? cells, NK cells, and SPCs
(3 9 106/ml) were activated for 24 h with Con A (Sigma–
Aldrich) (1.5 mg/ml) in the absence (activated cells) or in
the presence of human IL-12 (R&D) (10 ng/ml) (stimu-
lated cells). RPMI 1640 medium (Sigma–Aldrich) with
10 % FCS was used. Co-culture experiments were per-
formed in Transwell systems (0.4 lm, BD Biosciences)
with subconfluent ECs (7 9 104) plated at the bottom of
the wells and lymphocytes (1.5–3 9 106/ml) seeded onto
the inserts. Both cell types were in RPMI 1640 medium
with 10 % FCS [22, 23].
CAM angiogenesis assay
Fertilized chicken eggs were incubated at 37 C in a
humidified incubator. PBMCs, activated or stimulated
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PBMCs were resuspended to a final density of 1.5 9 106
cells in 50 ll of RPMI 1640 medium, embedded in Ma-
trigel basement membrane matrix (BD Biosciences) and
added on the CAM at day 10 of incubation with or without
basic fibroblast growth factor (bFGF) (R&D Systems)
(100 ng). After 48 h of incubation, CAMs were fixed with
3.7 % paraformaldehyde for 10 min at room temperature.
Pictures were taken with a JVC TK-C1380E color video
camera (ImageProPlus 4.0 imaging software) connected to
the stereomicroscope (model SZX9; Olympus). Pictures
were processed with the imaging software winRHIZO Pro
(Regent Instruments Inc.) [27].
Immunoprecipitation, immunobloting
and cell extract preparations
Immunoprecipitation and blot analysis were performed
accordingly to our routine procedures on ECs [25]. Lysis
buffer contained protease and phosphatase inhibitors, and
Triton X-100 as detergent. For immunoprecipitation
experiments cell lysates were divided into two aliquots:
one part was immunoprecipitated as indicated, while the
other part was kept unprocessed and directly used as con-
trol of the total level of co-immunoprecipated proteins.
In some experiments, protein detection was performed
on nuclear, cytosolic or membrane fractions of ECs. To
separate the cytosol from nuclear fraction, cells were lysed
in 300 ll of ice cold lysis buffer (20 mM Tris–HCl, pH 8.0
containing 20 mM NaCl, 0.5 % Nonidet P-40, 1 mM DTT
and protease and phosphatase inhibitors). Cells were
resuspended by pipetting and then incubated on ice for
5–10 min. After centrifugation at 10,0009g for 10 min at
4 C, supernatant containing cytosolic proteins was col-
lected and pellet was resuspended in 60 ll of 20 mM
HEPES buffer (pH 8.0, containing protease inhibitors,
25 % glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 5 mM DTT). After 30 min on ice, suspension was
centrifuged at 10,0009g for 10 min at 4 C and superna-
tant containing nuclear proteins was diluted (1:3) in the
same buffer. To separate the cytosol from membrane
fraction, ECs were harvested and rapidly sonicated at 4 C
in 100 ll of 10 mM HEPES buffer (pH 7.5, containing
10 mM 2-mercaptoethanol, 5 mM EDTA, 10 % glycerol,
0.24 M sucrose and protease inhibitors). The lysate was
centrifuged at 10,0009g for 40 min at 4 C. The super-
natant, corresponding to the cytoplasmic fraction, was
collected and membrane pellets were solubilized in the
same buffer containing 1 % Triton X-100.
Western blot quantification was performed measuring
band intensity by scan-densitometry with Phoretix 1D
software (Nonlinear USA, Durham, NC). Changes in pro-
tein amount were quantified after normalization procedure.
The following Abs were used: anti-p21Cip1/Waf1 (#AF1047;
goat), anti-p27kip1 (#AF2256; goat), anti-p53 (#AF1355; goat),
anti-phospho-STAT1-Y701 (#AF2894; rabbit), anti-phospho-
p38 MAPK-T180/Y182 (#AF869; rabbit), anti-CD31 (#BBA7;
mouse) were from R&D Systems; anti-p16INK4b (sc-71805;
mouse), anti-p18INK4c (sc-9965; mouse), anti-p57kip2 (sc-
56341; mouse), anti-cyclin E (sc-56311; mouse), anti-Cdk2
(sc-53220; mouse), anti-STAT1 (sc-73070; mouse), anti-
phospho-STAT1-S727 (sc-16570; goat), anti-PKCd (sc-8402;
mouse), anti-GAPDH (sc-48166; goat) were from Santa Cruz
Biotechnology; anti-pan-p38 MAPK (#9212; rabbit), anti-p38a
MAPK (#9228; mouse) were from Cell Signaling; anti-nuclear
matrix p84 (ab94812) was from Abcam.
Cell cycle analysis
ECs were suspended in 50 ll of phosphate-buffered saline
(pH 7.4) (PBS), fixed in 1 ml of 70 % ice-cold ethanol for
30 min on ice, stained with 0.5 ml of propidium iodide
100 lg/ml (Sigma-Aldrich) containing 5 lg/ml pancreatic
RNase (Stratagene) for 20 min at 37 C. After gating out
cellular aggregates and debris, propidium iodide fluores-
cence was measured by flow cytofluorometry, and cell
cycle analysis was performed with the Mod Sit LT program
(Verity Software House) [22, 23]. DNA synthesis was
measured by 5-bromo-2-deoxyuridine (BrdU) uptake and
compared with DNA content as determined by propidium
iodide uptake [28]. Briefly, adherent cells were incubated
with 30 lM BrdU (Sigma–Aldrich; 1 h at 37 C).
Detached cells were fixed as described above, washed, and
suspended in PBS. Cells were denatured in 1 ml of 2 N
HCl for 20 min at room temperature and then neutralized
with 1 ml of 0.1 M Na2B4O7 for 5 min at room tempera-
ture. The cells were centrifuged and incubated (10 min at
45 C) in 2 ml of PBS containing 5 % Tween 20 and 0.1 %
BSA, then centrifuged and incubated with 10 lg of fluo-
resceinated mAb anti-BrdU (PharMingen) in 0.2 ml of
PBS for 30 min at room temperature in the dark. After
washes the cells were kept overnight at 4 C in the dark to
favor partial DNA renaturation. Staining with propidium
iodide and flow cytofluorometry were performed as
described above. At least 10,000 events were analyzed.
Protein down-modulation by siRNA
The day before oligofection, ECs were seeded at a density
of 1 9 105 cells/well in 6-well plates. Two hundred pmoles
of non-targeting (as control) or targeting siRNAs were
transfected twice (at 0 and 24 h) in the presence of Lipo-
fectamine (Invitrogen) according to manufacturer’s proto-
col. siRNA duplexes for PKCd (AAG ATG AAG GAG
GCG CTC AG) were obtained from Qiagen. In the case of
p21Cip1/Waf1, STAT1 and p38 MAPK siGENOME SMART
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pools (Dharmacon) were used. Non-targeting duplexes
were purchased from Dharmacon. 24 h after the second
oligofection, ECs were lysed or tested in functional assays.
Supplementary Figure S1 shows the level of target protein
down-regulation exerted by specific targeting siRNAs. In
some experiments, ECs carrying the target siRNAs were
transfected with the vectors containing the cDNA corre-
sponding to the gene of interest [pMT5-Flag-p21Cip1/Waf1
(Addgene plasmid 16240), pLTR-PKCd (Addgene plasmid
8419), pRC/CMV-STAT1a-Flag (Addgene plasmid 8691),
pRC/CMV-STAT1a S727A (Addgene plasmid 8700),
pMT3-p38 (Addgene plasmid 12658)] by Lipofectamine.
Statistical analysis
Data are expressed by mean of at least 3–4 experiments and
SD is indicated. Differences are analyzed by ANOVA
followed by Bonferroni’s test (SPSS Statistics 16.0).
Results
IL-12-stimulated PBMCs inhibit angiogenesis
We previously reported that ECs challenged with ConA-
activated PBMCs stimulated with IL-12 modify their
angiogenic in vitro potential as consequence of a reduction
of proliferative rate and a modification of the proteolytic
activity [22, 23]. We extended these observations to CAM
angiogenesis assay. Matrigel containing PBMCs alone or
with bFGF (100 ng) was applied to 10-day-old embryo
CAMs. As shown in Fig. 1, PBMCs or Con A-activated
PBMCs (activated PBMCs) do not inhibit the bFGF-pro-
moted CAM vessel branching and remodeling. On the
contrary, activated PBMCs challenged with IL-12 (stimu-
lated PBMCs) dramatically impaired the angiogenic effect
triggered by bFGF (Fig. 1).
Stimulated PBMCs inhibit EC cycle through
a p21Cip1/Waf1-dependent mechanism
EC proliferation rate in CAM assay is very fast up to day 6,
then starts to decline and it is reduced to half at day 10. The
addition of an angiogenic molecule induces a clear increase
in proliferative activity, which is evident after 2 days [29].
Therefore, we aimed at expanding our previous results that
showed the blocking activity of stimulated PBMCs on EC
cycle [23]. We investigated the expression of CDK inhib-
itors in ECs co-cultured for 48 h with PBMCs, activated
PBMCs or stimulated PBMCs. p21Cip1/Waf1, a member of
Cip/Kip family, seems to be the principal endothelial tar-
get. PBMCs alone slightly reduced the expression of
p21Cip1/Waf1, which returned to the basal level in the
presence of activated PBMCs and markedly increased with
stimulated PBMCs (Fig. 2a). This effect is mimicked by
purified CD4? cells, but not by CD8? or NK cells
(Fig. 2b). The expression of other members of Cip/Kip
(p27Kip1 or p57Kip2) and INK4 (p16 INK4b, p18 INK4c)
inhibitor families were not affected by the different con-
ditions of co-culture (Supplementary Figure S2). The G1/S
transition is dependent on activation of the cyclin E/Cdk2
complex, which is negatively regulated through the binding
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Fig. 1 Stimulated PBMCs inhibit bFGF-mediated angiogenesis. Ten-
day-old CAMs were challenged with PBMCs (a, b), activated PBMCs
(c) or stimulated PBMCs (d), and left untreated (a) or treated
(b–d) with bFGF (100 ng). After 48 h fixed CAMs were photo-
graphed. (e) The angiogenic index was determined by the imaging
software winRHIZO Pro and expressed as number of vessel forks/
mm2. Values shown are mean ± SD of four independent experi-
ments, each in triplicate. Statistical significance (p \ 0.001) is shown
for CAM with PBMCs compared with CAM treated with bFGF in the
presence of PBMCs or activated PBMC (*) and CAM treated with
bFGF in the presence of stimulated PBMCs compared with CAM
treated with bFGF in the presence of PBMCs or activated PBMC (§)
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with p21Cip1/Waf1 [30]. Figure 2c shows that more cyclin E
and Cdk2 are recruited by p21Cip1/Waf1 supporting the
concept that stimulated PBMCs influence EC cycle at G1/S
transition. Interestingly, PBMCs alone reduce the amount
of cyclin E and Cdk2 associated with p21Cip1/Waf1 while the
interaction with Cdk2, but not with cyclin E is already
promoted by activated PBMCs (Fig. 2c).
A further analysis of the role of p21Cip1/Waf1 was
performed by using cells depleted of this protein. In a first
set of experiments we used mouse aortic ECs isolated
from p21Cip1/Waf1-/- mice. SPCs activated by ConA
(activated SPCs) and subsequently challenged with mur-
ine IL-12 (stimulated SPCs) induced a cell accumulation
in G0/G1 phase and a reduction in S phase (Fig. 3a). In
striking contrast, the cell cycle of ECs from p21Cip1/Waf1-/-
mice resulted to be similar in all co-culture conditions
(Fig. 3a).
To further support the results obtained with p21Cip1/Waf1-/--
ECs, we silenced the expression of p21Cip1/Waf1 in human
ECs by RNA interference. After down-modulation of
p21Cip1/Waf1, stimulated PBMCs were unable to arrest EC
cycle in G1 phase (Fig. 3b). However, after transfection of
p21Cip1/Waf1 cDNA, silenced ECs normally responded to
stimulated PBMCs (Fig. 3b). Of note, in ECs co-cultured
with PBMCs the greater cell percentage observed in G1
phase is likely caused by transfection-induced overexpres-
sion of p21Cip1/Waf1 that mimics the effect of p21Cip1/Waf1 up-
regulation exerted by stimulated PBMCs on ECs.
Stimulated PBMCs modulate p21Cip1/Waf1 by different
mechanisms involving STAT1, PKCd, p38 MAPK,
but not p53
The cellular amount of p21Cip1/Waf1 is regulated at tran-
scriptional level by both p53-dependent and -independent
mechanisms [24]. Furthermore, post-transcriptional mech-
anisms involving mRNA or protein stabilization have been
described to influence the cellular behavior of p21Cip1/Waf1
[24, 31–35]. We firstly investigated the role of p53 tumor
suppression protein that is considered pivotal in p21Cip1/Waf1
regulation in stressed cells [24]. This aspect was studied by
both evaluating the p53 expression in ECs co-cultured with
PBMCs and by using ECs isolated from p53-/- mice.
Western blot analysis showed that p53 level did not change
in ECs co-cultured with PBMCs or activated PBMCs but it
dropped when ECs were co-cultured with stimulated
PBMCs (Fig. 4a). Furthermore ECs from p53-/- mice
normally responded to stimulated SPCs with an evident
accumulation in G1 phase (Fig. 4b). Altogether these data
exclude a major role of p53 in up-regulating p21Cip1/Waf1.
We previously demonstrated that IFNc is partially
involved in EC response to stimulated PBMCs [23]. Indeed
we investigated the role played by STAT1, a transcription
factor that binds p21Cip1/Waf1 promoter [36] and is involved
in IFNc-mediated cell activation [37]. Stimulated PBMCs
specifically induced an increase in STAT1 expression and
phosphorylation on both Y701 and S727 (Fig. 5a), as well
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Fig. 2 Effects of PBMCs on
p21Cip1/Waf1 expression (a,
b) and co-immunoprecipitation
with cyclin E and Cdk2 (c).
Human ECs were cultured
(48 h) alone or with PBMCs,
activated or stimulated PBMCs
(a, c) or with stimulated purified
CD4?, CD8? and NK cells (b).
At the end of incubation,
proteins from EC lysates [a, b,
and c (lower three blots)] or EC
anti-p21Cip1/Waf1 immunoprecipitates
(c, upper three blots) were
separated and blotted as
indicated. Figures are
representative of 3–4
independent experiments. See
Supplementary Figure S3a and
b for the densitometric
quantification of the data shown
in panel a and b, respectively
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as STAT1 nuclear translocation in co-cultured ECs
(Fig. 5b). The induced tyrosine phosphorylation and
nuclear translocation of STAT1 indicates its activation
[38]. Interestingly serine phosphorylation has been dem-
onstrated to further enhance transcriptional activity at
maximal levels [39]. Depletion of STAT1 by siRNA oli-
gonucleotide (siSTAT1) transfection reduced the up-regu-
lation of p21Cip1/Waf1 induced by stimulated PBMCs
(Fig. 5c). This effect was partially and completely reversed
by transfecting STAT1 depleted cells with S727A-STAT1
and STAT1 cDNAs, respectively (Fig. 5c). In parallel,
stimulated PBMCs-induced effect on G1/S transition was
reduced in STAT1 depleted cells and rescued by trans-
fecting STAT1 cDNA (Fig. 5d).
A further mechanism of cell cycle control involves PKC
pathway [40]. In particular PKCd is implicated in the
regulation of G1/S progression through up-regulation of
p21Cip1/Waf1 [31, 35, 41, 42]. Blot analysis of cytosolic and
membrane proteins isolated from ECs clearly indicated that
PKCd was activated in cells co-cultured with stimulated
PBMCs, as inferred by its translocation from cytosol to
membrane fraction (Fig. 6a). By depleting PKCd using the
specific siRNA oligonucleotides (siPKCd), we investigated
the role of this kinase in controlling p21Cip1/Waf1 levels.
The PKCd down-modulation by siPKCd markedly reduced
the level of p21Cip1/Waf1 in ECs co–cultured with stimu-
lated PBMCs (Fig. 6b). The role of PKCd was further
supported by the use of the specific rottlein inhibitor [43].
As shown by Fig. 6c, 300 nM rottlein completely reverted
the block of cell cycle in G1 phase observed in ECs co-
cultured with stimulated PBMCs.
Besides transcriptional mechanisms, p21Cip1/Waf1 levels
may be controlled by activation of p38 MAPK, which
increases its stability [44, 45]. Stimulated PBMCs were able
to raise the level of phosphorylated p38 in ECs (Fig. 7a), and
its depletion by a specific siRNA (sip38) reduced p21Cip1/Waf1
increase (Fig. 7b) and partially impaired the modulation of
EC cycle by stimulated PBMCs (Fig. 7c). The rescue
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Fig. 3 Role of p21Cip1/Waf1on
the PBMCs-mediated regulation
of EC cycle. Cell cycle analysis
of murine ECs isolated from
p21Cip1/Waf1-/- mice (a) or
human ECs transfected with
sip21Cip1/Waf1, siCtl or
sip21Cip1/Waf1 and the specific
cDNA (b), co-cultured as
indicated for 72 h. At the end of
co-cultures cells were labeled
with BrdU, stained with
fluorosceinated Ab anti-BrdU
and propidium iodide, and then
analyzed by cytofluorimeter.
The most important differences
required for the interpretation of
the results are indicated by *
(p \ 0.05; n = 6)
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experiment performed with p38 cDNA indicated the speci-
ficity of the sip38 used (Fig. 7b, c).
Discussion
Innate immunity is an emerging mechanism to control the
vascular response to chronic injury. The circuit triggered
by IL-12 released by activated dendritic cells or macro-
phages involves the production of IFNc and IFNc-inducible
chemokines with angiostatic properties [16, 17, 19–21].
Firstly described in tumor [8], the activation of this axis
was subsequently reported in other diseases involving
vascular system, such as atherosclerosis [6]. By using a co-
culture model, in previous reports we analyzed the cellular
mechanisms required to accomplish the angiostatic activity
of IL-12 [22, 23]. Our initial studies indicated that CD4?
cells are the most important target of IL-12 to block ECs in
G1 phase and that CD8? and NK cells have cooperative
functions. In this system, the IFNc axis and in particular
CXCL9 and CXCL10 are the final effectors [23]. To better
understand the signaling mechanisms involved, we focused
on how PBMCs stimulated by IL-12 affect cycle progression
in ECs. We showed that the CDK inhibitor p21Cip1/Waf1 is a
key molecule in the negative control of cycle progression.
Actually, PBMCs or CD4? cells stimulated by IL-12 up-
regulate p21Cip1/Waf1 expression in ECs and its function is
crucial for EC cycle G1 arrest, as inferred by the use of
ECs isolated from p21Cip1/Waf1-/- mice and by the specific
siRNA-mediated depletion. Other CDK inhibitors belong-
ing to Cip/Kip or INK4 families are refractory to stimu-
lated PBMCs suggesting that their role is marginal or
absent. This result is consistent with the observation that
p21Cip1/Waf1 is the most important target of molecules
inhibiting EC growth [26, 46–52].
The mechanism by which stimulated PBMCs increase
the level of p21Cip1/Waf1 needs the combined activities of
several regulatory pathways that confer some degrees of
specificity to this system. By the use of different strategies
we demonstrated the active function of STAT1, PKCd and
p38 MAPK and excluded a role of p53 in regulating
p21Cip1/Waf1 levels and in control of EC cycle. In contrast
to other biological contexts, such as the activity of anti-
angiogenic compounds, the effect of shear stress and
senescence [46, 47, 51, 53, 54], p21Cip1/Waf1 activation in
ECs challenged with stimulated PBMCs does not require
p53 pathway. The demonstration was obtained by using
ECs isolated from p53-/- mice. These cells normally
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analysis of murine ECs isolated
from p53-/- mice and co-
cultured with SPCs for 72 h (b).
The most important differences
required for the interpretation of
the results are indicated by *
(p \ 0.05; n = 5). See
Supplementary Figure S3c for
the densitometric quantification
of the data shown in panel a
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accumulated in G1 when co-cultured with stimulated SPCs.
Furthermore, stimulated PBMCs did not promote an
increase of p53 in ECs, a landmark of the activation of this
pathway [24]. Interestingly, it has been reported that the
p21Cip1/Waf1-dependent cell cycle arrest by IFNc in human
leukemia and melanoma cells did not correlate with p53
[55, 56].
We identified three major pathways regulating the
increase of p21Cip1/Waf1. STAT1, a molecule involved in the
growth arrest effects of IFNs, has been reported to up-reg-
ulate p21Cip1/Waf1 transcription through a direct binding to its
promoter [36]. STAT1 phosphorylation at Y701 is mediated
by Jak and is a prerequisite for STAT1 dimerization, nuclear
translocation, and DNA binding [38]. In our experimental
conditions, this phosphorylation was notably increased and
detected in parallel with the nuclear translocation. Our data
are in agreement with the observation that STAT1 depletion
abrogated IFNc-induced inhibition of EC growth and in vitro
morphogenesis, as well as in vivo angiogenesis promoted by
vascular endothelial growth factor-A [57].
A second molecule involved is PKCd as inferred by the
use of the specific inhibitor rottlein [42] and specific
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Fig. 5 Role of STAT1 on the
PBMCs-mediated regulation of
EC cycle. Human ECs (a, b) or
ECs transfected with siSTAT1,
siSTAT1 and STAT1 S727A
cDNA, siSTAT1 and STAT1
cDNA, or siCtl (c) were
cultured alone or with PBMCs,
activated or stimulated PBMCs
for 48 h. At the end of
incubation proteins from EC
lysates (a, c) or from EC
cytosolic (b, upper two blots)
and nuclear fractions (b, middle
two blots) or whole cell lysates
(WCL) [b (lower two blots)]
were separated and blotted as
specified. At the end of co-
cultures, cell cycle was
analyzed by cytofluorometry
analysis as reported in the
legend to Fig. 3. The most
important differences are
indicated by * (p \ 0.05;
n = 5) (d). Blots in panels a–
c are representative of at least 4
experiments. In panel c, values
of densitometric analysis are
reported as fold-increase over
basal values in control cells,
after normalization for CD31
level; values are the
mean ± SD of three
independent experiments. See
Supplementary Figure S3d and
Supplementary Table S1 for the
densitometric quantification of
the data shown in panel a and b,
respectively
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siRNA oligonucleotides. In ECs co-cultured with stimu-
lated PBMCs, PKCd silencing reduced p21Cip1/Waf1 accu-
mulation and rottlein inhibited the cell cycle block. This
kinase generally slows proliferation and induces cell cycle
arrest in different ways [58]. A first target is transcriptional
and post-transcriptional regulation of cyclins D1 and E [31,
41]. A second mechanism is the elevation in p21Cip1/Waf1
transcript and protein [31, 35, 41, 42]. To notice that in an
acute promyelocytic leukemia cell line PKCd is activated
in an IFNc-dependent manner and that STAT1 S727 is a
substrate for its kinase activity [59]. Such serine phos-
phorylation does not modify the nuclear translocation of
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PBMCs-mediated regulation of
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ECs transfected with siPKCd
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At the end of incubation
proteins from EC cytosolic
(a, upper two blots) and
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two blots) or whole cell lysates
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specified. When indicated
(c) ECs were maintained in the
presence of 300 nM rottlein,
added every 24 h. At the end of
co-cultures cell cycle was
analyzed by cytofluorometry
analysis as reported in the
legend to Fig. 3. The most
important differences required
for the interpretation of the
results are indicated by *
(p \ 0.05; n = 4) (c). Blots in
panels a and b are
representative of at least 5
experiments. In panel b, values
of densitometric analysis are
reported as fold-increase over
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after normalization for CD31
level; values are the
mean ± SD of three
independent experiments. See
Supplementary Table S2 for the
densitometric quantification of
the data shown in panel a
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STAT1 or the DNA-binding capacity of STAT1 complexes
but it is required for maximal transcriptional activation of
IFNc-regulated genes [39]. In our system the maximal up-
regulation of p21Cip1/Waf1 required the phosphorylation of
STAT1on both Y701 and S727, suggesting the combined
activity of a Jak1- and a PKCd-dependent phosphorylation
of STAT1.
Although the PKCd-dependent up-regulation p21Cip1/Waf1
is an established event in different cell systems, its precise
molecular mechanism is still not fully understood.
Recently, it has been reported that PKCd increases
expression of Kruppel-like factor KLF4, which interacts at
GC-rich DNA elements in the proximal p21Cip1/Waf1 pro-
moter to activate p21Cip1/Waf1 gene transcription leading to
cessation of cell proliferation [60]. Interestingly, a previous
study indicated that KLF4 is a potential downstream target
of IFNc that mediates its growth inhibitory property [61].
In particular, the group of Chen and coworkers demon-
strated that IFNc-induced KLF4 expression required
phosphorylated STAT1 and that this effect is mediated, in
part, through interaction of STAT1 with the GAS element
on KLF4 promoter [62]. Therefore it is intriguing to
speculate that the maximal up-regulation of p21Cip1/Waf1
may result from the PKCd-mediated enhancement of
STAT1 transcriptional activity leading to both direct and
KLF4-mediated transcription of p21Cip1/Waf1.
Lastly, we found that stimulated PBMCs utilizes the
ability of p38 MAPK to stabilize p21Cip1/Waf1 [44, 45].
Actually stimulated PBMCs activate p38 phosphorylation
and p38 depletion overcomes the EC cycle arrest in G/G1
phase.
In conclusion, our findings suggest that the immune
circuit activated by IL-12 arrests EC cycle in G1 phase
mainly by the accumulation of CDK inhibitor p21Cip1/Waf1.
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Fig. 7 Role of p38 on PBMCs-
mediated regulation of EC
cycle. Human ECs (a) or ECs
transfected with sip38, sip38
and p38 cDNA, or siCtl
(b) were cultured (48 h) alone
(a) or with PBMCs (a, b),
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PBMCs (a, b). At the end of
incubation proteins from EC
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important differences required
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(p \ 0.05; n = 5) (c). Blots in
panels a and b are
representative of at least 4
experiments. In panel b, values
of densitometric analysis are
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level; values are the
mean ± SD of three
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Supplementary Figure S3e for
the densitometric quantification
of the data shown in panel a
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This effect results from the cooperation between STAT1,
PKCd and p38 MAPK, which act at transcriptional and
post-transcriptional levels (Fig. 8). Although the role of
these pathways have not directly analyzed in vivo, our in
vitro experiments suggest that they may really participate
to the in vivo inhibition of EC cycle triggered by the IL-12-
dependent circuit here described. Altogether, our results
provide insights into the molecular mechanisms by which
IL-12-activated innate immunity regulates EC proliferation
in chronic degenerative diseases including tumors and
atherosclerosis. Of interest, for long time IL-12 has been
considered a promising therapy in the treatment of malig-
nancies but its use has been recently discouraged for seri-
ous toxicity [8]. However recent data may allow re-
considering this cytokine as a therapeutic tool in selected
tumor subsets. Actually it has been reported that the in vivo
tumor response to IL-12 is influenced by the molecular
features of its receptor [63] and that IL-12 could be a
candidate for tumor shrinkage observed during the treat-
ment of early-stage non-small cell lung cancer with tyro-
sine kinase inhibitors (vandetanib, pazopanib) targeting
angiogenic receptors [64, 65].
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